Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Remission Induction and Sustenance in Graves' Disease 2

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Peter Laurberg, Aalborg Hospital Identifier:
First received: November 21, 2008
Last updated: January 22, 2013
Last verified: January 2013

ATD therapy for Graves' disease is one of the commonly used options for therapy of the hyperthyroidism. The investigators study how to optimally keep patients in remission.

Condition Intervention Phase
Graves Disease
Other: Stop medication
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy

Resource links provided by NLM:

Further study details as provided by Aalborg Universitetshospital:

Primary Outcome Measures:
  • Relapse of hyperthyroidism [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Reoccurrence of TSH-receptor autoimmunity [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 250
Study Start Date: January 2008
Estimated Study Completion Date: January 2016
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Stop of medication after remission Other: Stop medication
Stop medication Stop medication + se supplement
Other Names:
  • stop medication
  • stop medication + se supplement
No Intervention: Medication for 2 yrs after remission
Experimental: Se-yeast 200 Microgr/day + arm A Other: Stop medication
Stop medication Stop medication + se supplement
Other Names:
  • stop medication
  • stop medication + se supplement


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Graves hyperthyroidism in remission after ATD

Exclusion Criteria:

  • Age < 18, severe concomitant disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00796913

Sponsors and Collaborators
Aalborg Universitetshospital
Principal Investigator: Peter Laurberg, MD Aalborg Universitetshospital
  More Information

No publications provided

Responsible Party: Peter Laurberg, Professor of Endocrinology and Internal medicine, Aalborg Hospital Identifier: NCT00796913     History of Changes
Other Study ID Numbers: RISG2
Study First Received: November 21, 2008
Last Updated: January 22, 2013
Health Authority: Denmark: Ethics Committee

Additional relevant MeSH terms:
Graves Disease
Autoimmune Diseases
Endocrine System Diseases
Eye Diseases
Immune System Diseases
Orbital Diseases
Thyroid Diseases processed this record on November 27, 2014